Clearmind Medicine Inc. · NASDAQ:CMND
Clearmind Medicine — Investor Presentation (November 2025)
24 slides from Clearmind Medicine's investor presentation, November 2025
Slide 1: Novel Psychedelics for Treating Addictions, Obesity & Mental Health
Novel Psychedelics for Treating Addictions, Obesity & Mental Health Corporate and Science Presentation | November 2025 NASDAQ: CMND FSE: CWY0 www.ClearmindMedicine.com Clearmind Medicine Inc.
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements All statements in this presentation, other than those relating to historical facts, are "forward‐looking statements.” Forward-looking statements contained in this presentation include, but are not limited to, statements regarding Clearmind Medicine Inc. (the
Slide 3: About Clearmind
About Clearmind Why Psychedelics? Psychedelic compounds are increasingly being studied and many believe represent the future for treatment of a variety of mental health disorders. Clearmind’s solutions for addiction, especially alcoholism and obesity, hold the potential to better the lives of millio
Slide 4: Pipeline
Pipeline Clearmind Medicine Inc. Corporate Presentation | November 2025 Page 4
Slide 5: Alcohol Use Disorder
Alcohol Use Disorder Only 4 FDA approved medicines for AUD Approved by FDA Average $/Month Clearmind’s flagship treatments are Antabuse Disulfiram 1949 $42 focused on Alcohol Use Disorder (AUD), which is extremely common. Campral 2004 $125 Acamprosate The yearly cost of excessive alcohol ReVia 1994
Slide 6: Alcohol Use Disorder (AUD) among US Veterans
Alcohol Use Disorder (AUD) among US Veterans VA studies suggest that 10% of American veterans meet the criteria for AUD. RAND Epstein Family Veterans Policy Research Institute. https://www.rand.org/pubs/infographics/IGA1363-4.html About 11% of veterans using VA healthcare have a substance use disord
Slide 7: Clearmind's solution is its flagship proprietary molecule: MEAI
Clearmind’s solution is its flagship proprietary molecule: MEAI or 5-Methoxy-2-aminoindane MEAI is a non-hallucinogenic Acts as a selective serotonin Has been recreationally used by many To date, Clearmind is not psychoactive molecule of the 2- releasing agent, with 6-fold people, who reported a red
Slide 8: MEAI Mechanism of Action
MEAI Mechanism of Action The efficacy and mechanism of action of MEAI has been investigated in vitro as well as in vivo In vitro binding studies established interactions mainly with the serotonergic system. MEAI was found to interact with the following receptors or enzymes: serotonin 5HT1A, 5HT2A, 5
Slide 9: Clearmind's First In-Human Clinical Trials: CMND-100 for Alcohol Use Disorder
Clearmind’s First In-Human Clinical Trials: CMND-100 for Alcohol Use Disorder Part A-Single Dose ~ 24 HV Part C-Multiple Dose 18 HV Study design: 4 Ascending Dose Cohorts (6 HVs per Cohort) Randomized Part -2:1 20 mg → next dose ratio Phase I/IIa No toxicity to 2, Grade 1 or up to 2 HVs with Grade (
Slide 10: Ongoing clinical programs: Clinical sites
Ongoing clinical programs: Clinical sites CMND-100 for Alcohol Use Disorder Johns Hopkins School of Medicine Hadassa-University Medical Center Baltimore, MD, USA. Jerusalem, Israel Principal investigators: Jennifer Ellis, PhD and Professor Eric Strain, MD. Principal Investigator: Prof. Joseph Karko,
Slide 11: Pre-clinical results in alcohol consumption
Pre-clinical results in alcohol consumption Pre-clinical in vivo trials demonstrated a significant and immediate reduction effect on alcohol consumption. The efficacy of MEAI in reducing alcohol consumption in mice was evaluated in an in vivo alcoholism model involving intermittent access to 20% alc
Slide 12: Pre-clinical trial in treating obesity
Pre-clinical Pre-clinical trial in treating obesity results in treating Obesity • Led by Prof. Joseph Tam, DMD, PhD, head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research and Dr. Saja Baraghithy, PhD. • 3 groups o
Slide 13: Pre-clinical results in treating obesity
Pre-clinical Pre-clinical results in treating obesity results in treating Obesity Results for the 3rd group - high-fat diet group treated with MEAI • Weight loss of 20% • Reduction in fat mass and preservation of lean body mass • Increased energy metabolism • No effect on motivation and well-being •
Slide 14: Pre-clinical results for cocaine addiction
Pre-clinical results for cocaine addiction In vivo research studies suggested that MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process. MEAI’s effect on cocaine addiction was evaluated utilizing male Sprague Dawley rats (Bar-Ilan University S
Slide 15: Pre-clinical results for cocaine addiction
Pre-clinical results for cocaine addiction The Effect of MEAI on the Substance-Use-Disorder 100 Coc-Saline (SUD) Rat Model using Cocaine as the Substance of Active lever presses (1h) Coc-MEAI Abuse The 5 mg/kg dose was also found to significantly reduce the preference for 50 cocaine in the CPP parad
Slide 16: MEAI Pre-clinical Safety
MEAI Pre-clinical Safety Results demonstrated low toxicity and a strong safety profile Summary of the Toxicology program for MEAI Clearmind Medicine Inc. Inc. Medicine Corporate CorporatePresentation Presentation ||October November 2021 2025 Page 16
Slide 17: The Clearmind Advantage
The Clearmind Advantage Next-gen and non- MEAI is a next generation psychedelic, that does not induce hallucinations and is not addictive. MEAI is potentially effective for alcoholism, cocaine addiction and obesity. hallucinogenic Accessible treatment CMND-100 is designed to be self-administered, du
Slide 18: IP Portfolio
IP Portfolio: MEAI: 2 mature families for binge behaviour regulators and alcoholic beverage substitute MEAI + PEA: 4 families for combination treatment for binge behaviour, cocaine addiction, obesity and metabolic 31 granted patents syndrome, and depression in major jurisdictions such as the US, 6 f
Slide 19: Strong and Experienced Management Team
Strong and Experienced Management Team Alan Rootenberg, CPA Adi Zuloff-Shani, PhD Mark Haden, MSW Chief Financial Officer Chief Executive Officer VP Business Development Mr. Alan Rootenberg is a chartered professional accountant who has Dr. Adi Zuloff-Shani is a Biomedical Research and Development P
Slide 20: Team of International Experts
Team of International Experts Mary-Elizabeth Sara Horn, PhD Nick Kadysh Gadi Levin, MBA Amit Shwartz, MSc Gifford Clinical and Regulatory Special Advisor VP Finance R&D Consultant Affairs Alcohol Substitute Program Chief of Global Impact Shannon Smadella Yael Stav, PhD Mylene Touboul Adi Varon Commu
Slide 21: Award-Winning Advisory Board
Award-Winning Advisory Board Prof. John Krystal Prof. Fatima Stanford Prof. Henry R. Kranzler Prof. Alon Friedman Prof. Christian Schütz MD , Yale University, CT, MD, MPH, MPA, Harvard Medical MD, PhD, University of Pennsylvania, MD, PhD, Dalhousie University, MD, PhD, University of British School,
Slide 22: Award-Winning Advisory Board
Award-Winning Advisory Board Prof. Wim van den Brink Prof. Gabriele Fischer Prof. Michael Davidson Prof. Joseph Tam MD, PhD, University of Amsterdam, MD, PhD, Medical University MD, Israeli Medical Centre for DMD, PhD, Hebrew University, The Netherlands Vienna, Austria Alzheimer, Israel Israel Wim v
Slide 23: Highly Accomplished Board of Directors
Highly Accomplished Board of Directors Amitay Weiss Oz Adler Yehonatan Shachar Asaf Itzhaik Hila Kiron-Revach Chairman of the Board Director Director Director Director Mr. Amitay Weiss has served Chairman of our Board Mr. Oz Adler has served as our Director since Mr. Yehonatan Shachar has served as
Slide 24: Let's make history together.
Let's make history Join our journey together. Investor Relations US: CMND@crescendo-IR.com invest@clearmindmedicine.com clearmindmedicine.com Clearmind Medicine Inc. Corporate Presentation | November 2025 Page 24
Clearmind Medicine — Investor Presentation (November 2025) on 6ix